The AstraZeneca vaccine (or Oxford vaccine, as it is sometimes known), is made in this way, using a modified chimpanzee cold virus to deliver the SARS-Cov2 spike protein into the body. This vaccine is currently in Phase Three trials at various sites around the world. Initial data is encouraging, and it is currently considered to be one of the front-runners in the vaccine race, but it might not be the ‘winner’. Trials have now been paused twice to investigate possible rare reactions.